1. The Cell Bank System
The master cell bank (MCB) and working cell bank (WCB) together form the two-tiered cell bank system required by ICH Q5D for biologics manufacturing. The master cell bank is the permanent reference pool (200–500 vials) created once from the production clone; the working cell bank is derived from a single MCB vial and provides the routine GMP starting material (100–300 vials). Understanding the difference between master cell bank and working cell bank — and managing both correctly — is the foundation of lot-to-lot consistency, regulatory compliance, and long-term product supply over a 20+ year product lifecycle.
Without a properly managed cell bank system, the cells used in Year 1 of commercial manufacturing cannot be guaranteed to be genetically and phenotypically identical to those used in Year 20. This tiered MCB → WCB structure protects the irreplaceable master cell bank from unnecessary use while providing a practical supply of cells for manufacturing campaigns.
Production Clone
↓ expansion & banking
Master Cell Bank (MCB) — 200–500 vials
↓ single vial thaw & expansion
Working Cell Bank (WCB) — 100–300 vials
↓ single vial thaw & seed train
Production Bioreactor
↓ harvest at limit of in vitro cell age
End of Production Cells (EoPC) — characterization
Each tier has distinct purposes, characterization requirements, and regulatory expectations. ICH Q5D (“Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products”) provides the regulatory framework, supplemented by ICH Q5B (genetic stability) and regional guidance documents.
2. Master Cell Bank (MCB)
The MCB is generated once from the selected production clone and serves as the permanent source material for the product’s entire commercial lifecycle. For a blockbuster monoclonal antibody, this can mean 20+ years of manufacturing from a single banking event. The MCB is the most critical and irreplaceable material in a biologics program.
Key Characteristics
- Size: Typically 200–500 vials (1–2 mL per vial at 5–20 × 106 cells/mL). Must be large enough to support QC testing, stability programs, backup storage, WCB generation, and regulatory retention for the entire product lifecycle.
- Generation: Produced from a single cell expansion of the production clone under controlled, documented conditions. The passage number (population doubling level) at MCB creation must be defined and recorded.
- Characterization: Extensive testing required—identity (STR profiling, isoenzyme analysis), purity (sterility, mycoplasma), viral safety (in vitro, in vivo, TEM, RT activity, PCR panels), genetic characterization (transgene sequence, copy number, integration site), and productivity confirmation.
- Storage: Minimum two geographically separated storage locations. Vapor-phase liquid nitrogen (≤−150°C). Continuous temperature monitoring with alarm systems.
The MCB should never be used directly for production. Its sole purpose is to generate WCBs. Every MCB vial thawed for WCB generation or QC testing is irreplaceable—plan your vial allocation carefully from the start.
3. Working Cell Bank (WCB)
Each WCB is generated by thawing a single MCB vial, expanding the cells through a defined passage series, and cryopreserving the resulting cell population. The WCB is the direct starting material for production: each manufacturing batch begins with the thaw of one WCB vial, followed by seed train expansion into the production bioreactor.
Key Characteristics
- Size: Typically 100–300 vials. Each WCB supports approximately 50–200 production batches (one vial per batch plus QC and stability testing).
- Generation: From a single MCB vial. The number of passages between MCB thaw and WCB cryopreservation must be defined and consistent for each WCB generated.
- Characterization: Less extensive than MCB. Typically includes identity (abbreviated panel), sterility, mycoplasma, in vitro virus testing, and confirmation of productivity and growth characteristics.
- Renewal: When a WCB is depleted, a new WCB is generated from a fresh MCB vial. The new WCB must meet the same acceptance criteria as the original.
The passage number at WCB creation, combined with the number of passages during seed train expansion to production scale, determines the in vitro cell age at the end of production. This cell age must be within the validated range demonstrated by EoPC characterization.
Plan your WCB size based on projected commercial demand. If you anticipate 50 batches per year and your WCB vials support 5 years of production, you need at least 250 production vials plus QC and stability vials. Under-sizing the WCB forces more frequent WCB generation from MCB vials, depleting your finite MCB supply faster.
4. End of Production Cells (EoPC)
End of Production Cells are harvested from the production bioreactor (or a representative scale-down model) at or beyond the maximum in vitro cell age used in manufacturing. EoPC characterization is an ICH Q5D requirement that demonstrates the production cell line remains genetically stable and free of adventitious agents across the entire production window.
What EoPC Testing Demonstrates
- Genetic stability: The transgene sequence, copy number, and expression level are maintained at the limit of cell age. No significant mutations, deletions, or rearrangements in the coding region.
- Phenotypic stability: Growth characteristics (specific growth rate, viability profile) and productivity (specific productivity, product quality attributes) are consistent with early-passage cells.
- Viral safety: In vitro and in vivo virus testing, TEM, and RT activity at EoPC cell age confirm no emergence of adventitious agents during extended culture.
The cell age at EoPC must equal or exceed the maximum cell age that will be encountered during commercial manufacturing. This includes all passages from WCB thaw through seed train expansion to the end of the production bioreactor run. If you later extend your production duration or add seed train passages, you may need to repeat EoPC characterization at the new maximum cell age.
5. Vial Planning
Proper vial allocation at the time of banking prevents costly mistakes later. Too few vials means insufficient material for QC testing, stability programs, or regulatory retention. The following tables provide guidance for typical MCB and WCB vial allocation.
MCB Vial Allocation
| Category | Vials | Purpose |
|---|---|---|
| QC characterization | 30–50 | Identity, sterility, mycoplasma, viral testing, genetic characterization |
| Stability program | 20–30 | Testing at 0, 6, 12, 24, 36, 60 months (viability, VCD, growth, productivity) |
| WCB generation | 10–20 | One vial per WCB; allows 10–20 WCBs over product lifecycle |
| Regulatory retention | 20–30 | Retained for product lifecycle + post-marketing per regional requirements |
| Backup/contingency | 50–100 | Stored at secondary site; covers unforeseen needs, re-testing, investigations |
| Process development | 20–40 | Cell line comparability, technology transfer, post-approval changes |
| Total MCB | 200–400+ |
WCB Vial Allocation
| Category | Vials | Purpose |
|---|---|---|
| QC characterization | 15–25 | Identity, sterility, mycoplasma, in vitro virus testing |
| Stability program | 15–20 | Testing at 0, 6, 12, 24, 36 months |
| Production batches | 50–200 | One vial per production batch |
| Retention/backup | 20–30 | Regulatory retention, contingency |
| Total WCB | 100–300 |
Plan Your Cell Bank
Use our Cell Bank Calculator to determine optimal vial counts based on your projected production schedule, QC requirements, and stability program.
Cell Bank Calculator →6. Storage & Cryopreservation
Proper cryopreservation and storage are essential for maintaining cell viability and functionality over decades. The two critical factors are the freezing protocol and long-term storage conditions.
Controlled-Rate Freezing
Cells must be frozen at a controlled rate of approximately 1°C per minute to prevent intracellular ice crystal formation while allowing sufficient dehydration. This is achieved using a controlled-rate freezer (CRF) that follows a programmed temperature profile, or—for less critical applications—an isopropanol-based passive cooling device (e.g., Mr. Frosty) placed in a −80°C freezer.
- Cryoprotectant: DMSO at 5–10% (v/v) is the standard. Higher concentrations provide better cryoprotection but increase cytotoxicity. Cells should be exposed to DMSO at 2–8°C and frozen promptly to minimize toxicity. Some programs use serum-free, chemically defined cryopreservation media to avoid animal-derived components.
- Cell density: Typically 5–20 × 106 viable cells/mL. Higher densities improve post-thaw recovery but increase the risk of post-thaw clumping.
- Vial format: 1.0 or 2.0 mL cryovials (external thread to prevent contamination). Some organizations are moving to closed-system cryobags for larger-volume banking.
Long-Term Storage
Cell banks must be stored in vapor-phase liquid nitrogen at −150°C or colder. Liquid-phase storage (−196°C) provides slightly lower temperatures but carries a risk of cross-contamination between vials through liquid nitrogen. Vapor-phase storage in well-maintained dewars typically maintains −150°C to −190°C and eliminates the cross-contamination risk.
Cell banks must be stored at a minimum of two geographically separated locations. A single catastrophic event—equipment failure, natural disaster, facility fire—must not be able to destroy the entire cell bank inventory. Many organizations maintain three storage sites: primary manufacturing site, secondary site within the organization, and a third-party contract storage facility.
Continuous temperature monitoring with alarm systems (including after-hours and weekend coverage) is a regulatory expectation. Temperature data must be recorded and retained as part of the cell bank documentation. Any temperature excursion above −130°C requires investigation and may necessitate re-testing of affected vials.
7. Regulatory Expectations
Cell bank management is governed by several ICH guidelines and regional regulatory documents. The key requirements are:
- ICH Q5D: Primary guideline for cell substrate derivation and characterization. Requires documentation of cell line history, cloning procedure, cell bank preparation, and characterization testing.
- ICH Q5B: Addresses genetic stability of the production cell line. Requires demonstration that the transgene and its expression are stable from MCB through EoPC at the limit of in vitro cell age.
- ICH Q5A: Viral safety evaluation. Requires viral testing of both MCB and WCB (see our Viral Clearance Strategy Guide).
- FDA Points to Consider (1993): Although dated, this document still provides useful guidance on cell bank testing requirements and is frequently cited by FDA reviewers.
What Regulators Look For
- Complete cell line history: From original tissue source through transfection, selection, cloning, adaptation, and banking. Every passage and manipulation must be documented.
- Clonality: Evidence that the production cell line was derived from a single cell. Limiting dilution cloning (with statistical evidence of single-cell origin) or automated single-cell deposition (FACS, ClonePix) with imaging documentation.
- Genetic stability: Transgene sequence confirmed at MCB and EoPC. Copy number and integration site stability demonstrated by Southern blot, ddPCR, or whole-genome sequencing.
- Freedom from adventitious agents: Comprehensive viral and microbial testing at MCB and WCB.
- Consistent performance: Growth rate, viability, and productivity within defined ranges from WCB thaw through production harvest.
8. Common Mistakes
Underestimating the number of vials needed for QC testing is the most common cell banking error. Viral safety testing alone (in vitro assays, in vivo assays, TEM, RT-PCR, adventitious agent PCR panels) can consume 15–20 vials. Add identity testing, mycoplasma, sterility, and genetic characterization, and you easily need 30–50 vials for MCB characterization. If you bank only 100 MCB vials, you may have insufficient material for both QC and WCB generation over the product lifecycle.
The stability of cryopreserved cells cannot be assumed—it must be demonstrated. Set aside dedicated stability vials at the time of banking and begin testing immediately (t = 0). Test at defined intervals (6, 12, 24, 36, 60 months) for post-thaw viability, viable cell density recovery, growth rate, and productivity. Retroactively establishing a stability program years after banking raises regulatory concerns.
Storing all cell bank vials in a single facility is an unacceptable risk. Equipment failures (LN2 supply interruption, dewar vacuum loss), facility events (fire, flood, power outage), or even human error (accidentally moving vials to an unmonitored freezer) can destroy an entire cell bank. Split your inventory across at least two geographically separated sites from the moment of banking.
Before committing to a full-scale banking run, always perform a pilot freeze-thaw study. Freeze a small number of vials (5–10) under the planned conditions, thaw them after 24–48 hours, and assess viability, recovery, and growth kinetics. If post-thaw viability is <80% or recovery is poor, optimize the cryopreservation protocol before banking the full lot. Discovering a failed banking protocol after you have already frozen 300 vials from a transient production clone is a costly mistake.
For clone selection and ranking before cell banking, see our Clone Scorecard. For seed train planning from WCB thaw to production scale, try the Seed Train Planner.
Frequently Asked Questions
What are the master cell bank and working cell bank?
The master cell bank (MCB) and working cell bank (WCB) are the two tiers of the cell bank system used in biologics manufacturing. The master cell bank is the permanent reference material, created once from a fully characterised production clone and typically stored as 200–500 cryovials in liquid nitrogen. The working cell bank is derived from a single MCB vial through expansion and re-banking, yielding 100–300 vials that serve as the routine starting material for GMP production runs. This two-tiered structure, defined in ICH Q5D, protects the irreplaceable MCB while providing practical supply for manufacturing.
What is the difference between a master cell bank and a working cell bank?
The difference between master cell bank (MCB) vs working cell bank (WCB) is primarily hierarchy and use. MCB is created first from the production clone, undergoes extensive characterisation (identity, purity, genetic stability, sterility, adventitious agents), and is used sparingly to generate WCBs. WCB is derived from one MCB vial, undergoes a shorter characterisation panel (identity, sterility, stability), and is used for routine manufacturing. MCB is the permanent reference; WCB is the working supply. One MCB typically produces 10–20 WCBs over a product lifecycle.
What is a master cell bank (MCB)?
A master cell bank (MCB) is a uniform pool of well-characterised cells derived from a single production clone, cryopreserved as multiple aliquots in liquid nitrogen. The MCB serves as the permanent starting material for all working cell banks (WCBs) throughout a biologic product’s lifecycle. ICH Q5D requires extensive MCB characterisation: identity testing (isoenzyme, STR profiling), purity (mycoplasma, adventitious agents, bacterial/fungal sterility), genetic stability, and productivity. A typical MCB contains 200–500 vials stored at −150°C or below.
What is a working cell bank (WCB)?
A working cell bank (WCB) is a pool of cells derived from a single master cell bank (MCB) vial through controlled expansion and re-banking, typically yielding 100–300 cryopreserved vials. The WCB is the routine starting material for GMP manufacturing: one WCB vial is thawed for each production campaign. WCBs undergo a reduced characterisation panel compared to MCBs (identity, sterility, mycoplasma, viability) because extensive MCB characterisation establishes the genetic baseline. Each new WCB must confirm it matches the MCB reference before release for manufacturing.
What does ICH Q5D require for master cell bank and working cell bank?
ICH Q5D requires that both master cell bank (MCB) and working cell bank (WCB) be derived from a single-cell clone, be uniformly distributed into individual cryovials, be tested for identity, purity (sterility, mycoplasma, adventitious agents), and genetic stability, and be stored under conditions that maintain viability (typically liquid nitrogen vapour phase below −150°C). MCB characterisation is more extensive (including full genetic stability and full adventitious agent panel); WCB characterisation focuses on confirming the WCB matches the MCB with no contamination introduced during the WCB preparation.
How many vials should be in a master cell bank or working cell bank?
A master cell bank (MCB) typically contains 200–500 vials (sometimes up to 1,000 for long-life products). A working cell bank (WCB) typically contains 100–300 vials. Size is driven by expected campaign frequency and product lifecycle: if you run 4 campaigns per year for 20 years, you need at least 80 WCB vials just for production, plus reserves for characterisation, stability studies, and regulatory submissions. Plan for at least 2 WCBs per MCB vial used, and retain at least 10–20% of the original MCB unused at any time as a regulatory safeguard.
What is ICH Q5D?
ICH Q5D (Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products) is the harmonised guideline that defines requirements for cell substrates used in biologics manufacturing. It specifies the two-tiered cell bank system (MCB and WCB), single-cell-clone derivation, full characterisation panels (identity, purity, sterility, mycoplasma, adventitious viruses, genetic stability), end-of-production cell (EoPC) testing, and cryostorage conditions. ICH Q5D is adopted by the FDA, EMA, PMDA, Health Canada, and other regional regulators, and forms the basis for cell bank sections of every biologics IND, BLA, MAA, and CTD submission.
What is the master cell bank definition?
The master cell bank definition (per ICH Q5D) is: an aliquot of a single pool of cells of uniform composition, derived from a single tissue or cell, distributed into multiple containers in one operation, processed together, and stored in a manner to ensure stability and uniformity. In practice, the MCB is created once per product from the chosen production clone, fully characterised for identity, purity, genetic stability, and adventitious agents, and stored as 200–500 cryovials in liquid nitrogen vapour phase below −150°C. The MCB is the permanent regulatory reference; all working cell banks (WCBs) trace back to a single MCB vial.
References
- ICH Q5D. “Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products.” International Council for Harmonisation, 1997.
- ICH Q5B. “Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products.” International Council for Harmonisation, 1995.
- FDA. “Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals.” Center for Biologics Evaluation and Research, 1993.
- Merten, O.W. (2015). “Advances in cell culture: anchorage dependence.” Philosophical Transactions of the Royal Society B, 370(1661), 20140040. doi:10.1098/rstb.2014.0040
- Tian, J., Stefanescu, R., & Wang, H. (2020). “Genetic stability of CHO cell lines: a review.” Biotechnology Advances, 43, 107575.